ALSA Ventures

ALSA Ventures investment thesis

Our approach Our investment approach is primarily focused around therapeutics. We look for novel drugs and modalities in a wide variety of disease areas, and invest across the spectrum of drug development. We are equally comfortable in company formation as we are in participating in syndicates with co-investors. Our process is heavily reliant on proprietary deal flow. With a rich history of working with hundreds of biotech companies and entrepreneurial teams in past lives, our team is particularly well networked globally to identify and evaluate novel, exciting breakthroughs. Once invested, we work in close partnership with management teams to execute R&D plans efficiently. Whilst the world of academic medical research is more inter-connected and collaborative than ever, we believe capital

ALSA Ventures team (6)

Partners and principals at ALSA Ventures:

• Robert Balfour — sweet spot $1.5M
• Lorna Collings — sweet spot $1.5M
• Julia Jones — sweet spot $1.5M
• Graeme R. Martin — sweet spot $1.5M
• Alek Safarian — sweet spot $1.5M
• Katie Sunnucks — sweet spot $1.5M

ALSA Ventures portfolio companies

Companies listed on ALSA Ventures's public materials include: SFDR Disclosure, ACCEPT, Our approach, Meet the Team, Portfolio, News, Eclipse, Investor Login, Visit Website, SFCR Disclosure, Remuneration Policy.

Is ALSA Ventures a fit for your round?

Upload your pitch deck and see whether anyone at ALSA Ventures appears in your top matches.